Rhenman & Partners Asset Management Ab Mirum Pharmaceuticals, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $766 Million
- Q2 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 65,755 shares of MIRM stock, worth $4.8 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
65,755
Previous 73,755
10.85%
Holding current value
$4.8 Million
Previous $3.32 Million
0.72%
% of portfolio
0.44%
Previous 0.4%
Shares
5 transactions
Others Institutions Holding MIRM
# of Institutions
230Shares Held
56.1MCall Options Held
25.3KPut Options Held
98.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$496 Million18.24% of portfolio
-
Janus Henderson Group PLC London, X05.24MShares$382 Million0.14% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$236 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.76MShares$201 Million5.52% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$192 Million2.55% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $2.68B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...